瑞士诺华地拉罗司图片及介绍

Novartis AG is a leading multinational company in the global pharmaceutical and consumer healthcare industries. Introduction to Novartis Deferasirox in Switzerland: (deferasirox) is an iron chelator product developed by Novartis Pharmaceuticals in Switzerland. It is the first oral iron-removing agent approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a first-line drug for patients with thalassemia iron overload over 6 years old.

Pictures of Swiss Novartis deferasirox:

Deferasirox dispersible tablets are an oral active chelating agent that is highly selective for iron (Fe3+). A multicenter, prospective clinical trial was conducted to evaluate the safety and efficacy of deferasirox in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS). The study selected patients with serum ferritin ≥1000 μg/L, transfusion dependence and red blood cell transfusions ≥20U to be included. The starting dose of deferasirox is 20 mg/kg/d, which can be adjusted up to 40 mg/kg/d.

A total of 176 patients were enrolled in the study, of whom 173 received treatment. 53% of patients completed 12 months of treatment (n=91) with a 23% decrease in mean serum ferritin, 36.7% of patients completed 2 years of treatment (N=49), and 36.5% completed 3 years of treatment (N=33). The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT. Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal. According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS.

Recommended hot articles: /newsDetail/88458.html